Mepolizumab, the active substance in Nucala, blocks a protein calledinterleukin-5. By blocking the action of this protein, the production of eosinophils by the bone marrow is limited, and the number of eosinophils in the blood and lungs is decreased.
No use Nucala:
Warnings and precautions
Consult your doctor before starting to use Nucala.
Worsening of asthma
Some people have asthma-related side effects, or their asthma may worsen during treatment withNucala.
Allergic reactions and at the injection site
Medications of this type(monoclonal antibodies)can cause severe allergic reactions when injected into the body (see section 4, “Possible side effects”).
If the child has ever had a similar reaction to any injection or medication:
Parasitic infections
Nucala may weaken the child's resistance to parasite-caused infections. If they already have a parasitic infection; it should be treated before starting treatment with Nucala. If they live in an area where these infections are common or if they are traveling to such an area:
Children and adolescents
This medication is not intended for use inchildren under 6 years old.
Other medications andNucala
Inform your doctorif the child is taking,has takenrecentlyor may need to take any other medication.
Other asthma medications
Pregnancy and breastfeeding
Pregnant patients, patients who think they may be pregnant, or patients who intend to become pregnant shouldconsult with their doctorbefore using this medication.
The components of Nucala are unknown to pass into breast milk.Pregnant patients should consult with their doctorbefore using Nucala.
Driving and operating machinery
It is unlikely that the possible side effects of Nucala will affect your ability to drive or operate machinery.
Nucala contains sodium
This medication contains less than 1mmol of sodium (23mg) per 40mg; this is essentially “sodium-free”.
Nucalais administered through an injection just under the skin (subcutaneous injection).
Your doctor or nurse will decide if you can administer Nucala to the child in your care. If they consider it appropriate, you will receive training to use Nucala correctly.
The recommended dosefor children aged 6 to 11 yearsis 40mg.It will be administered 1 injection every four weeks.
You can find the Pre-filled Syringe Instructions for use on the other side of the leaflet.
If you use more Nucala than you should
Consult your doctorif you think you may have administered too much Nucala.
If you forget a dose of Nucala
You must administer the next dose of Nucala as soon as you remember. If you do not realize you have forgotten a dose until it is time for the next one, administer only the next dose as planned. If you are unsure what to do, ask your doctor, pharmacist, or nurse.
If you interrupt treatment with Nucala
Do not stop administering Nucala injections unless your doctor tells you to. Stopping or interrupting treatment with Nucala may cause symptoms and asthma attacks to return in the child.
If the child's asthma symptoms worsen while receiving Nucala injections:
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. The side effects caused by Nucala are generally mild to moderate, although they can occasionally be severe.
Allergic reactions
Some people may have allergic reactions or allergic-type reactions. These reactions can be frequent (can affect up to 1 in 10 people). They usually occur within minutes to hours after the injection, but sometimes symptoms can start even several days later.
The symptoms may include:
If the child has ever had a similar reaction to any injection or medicine:
Other side effects include:
Very common::can affect more than 1 in 10 people
Common:can affect up to 1 in 10 people
Uncommon:can affect up to 1 in 100 people
Rare:can affect up to1 in 1000people
Reporting of side effects
If you experienceany type of side effect, consult your doctor or nurse, even if it is apossibleside effect that does not appear in this prospectus.You can also report themdirectlythrough thenational notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the label or on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in refrigerator (between 2°C and 8°C)
Do not freeze.
Store in original packaging to protect it from light.
The pre-filled syringe of Nucala can be removed from the refrigerator and stored in the outer packaging without opening for a maximum of 7 days at room temperature (below 30°C), and protected from light. Discard if left out of the refrigerator for more than 7 days.
Composition of Nucala
The active ingredient is mepolizumab.
Each 0.4ml of the pre-filled syringe contains 40mg of mepolizumab.
The other components are:sucrose, sodium phosphate dihydrate, citric acid monohydrate,polysorbate 80, disodium edetate,water for injection.
Appearance of the product and contents of the pack
Nucala is presented in a single-use pre-filled syringe as 0.4ml of a transparent to opalescent, colourless to pale yellow-brown solution.
Nucala is available in a pack containing 1 pre-filled syringe, or in a multiple pack containing 3 x 1 pre-filled syringes.
Marketing Authorisation Holder
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
Responsible for manufacturing
GlaxoSmithKline Manufacturing S.P.A
Strada Provinciale Asolana, No 90
43056 San Polo di Torrile, Parma
Italy
You can request more information about this medicine by contacting the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien GlaxoSmithKlinePharmaceuticalss.a./n.v. Tél/Tel: + 32 (0)10 85 52 00 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel: + 370 52 691 947 |
Luxembourg/Luxemburg GlaxoSmithKlinePharmaceuticalss.a./n.v. Belgique/Belgien Tél/Tel: + 32 (0)10 85 52 00 | |
Czech Republic GlaxoSmithKline, s.r.o. Tel: + 420 222 001 111 | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: + 36 23501301 |
Denmark GlaxoSmithKline Pharma A/S Tlf.: + 45 36 35 91 00 | Malta GlaxoSmithKline Trading Services Ltd. Tel: +356 80065004 |
Germany GlaxoSmithKline GmbH & Co. KG Tel.: + 49 (0)89 36044 8701 | Netherlands GlaxoSmithKline BV Tel: + 31 (0)332081100 |
Estonia OÜ Berlin-Chemie Menarini Eesti Tel: + 372 667 5001 | Norway GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Greece GlaxoSmithKlineΜονοπρ?σωπηA.E.B.E. Τηλ: + 30 210 68 82 100 | Austria GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 |
Spain GlaxoSmithKline, S.A. Tel: + 34 900 202 700 | Poland GSK Services Sp. z o.o. Tel.: + 48(0)22 576 9000 |
France Laboratoire GlaxoSmithKline Tél: + 33 (0)1 39 17 84 44 | Portugal GlaxoSmithKline – Produtos Farmacêuticos, Lda. Tel: + 351 21 412 95 00 |
Croatia Berlin-Chemie Menarini Hrvatska d.o.o. Tel: +385 1 4821 361 | Romania GlaxoSmithKline Trading Services Ltd. Tel: +40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenia Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: + 386 (0)1 300 2160 |
Iceland Vistor hf. Sími: + 354 535 7000 | Slovakia Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o. Tel: + 421 2 544 30 730 |
Italy GlaxoSmithKline S.p.A. Tel: + 39 (0)457741111 | Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Cyprus GlaxoSmithKline Trading Services Ltd. Τηλ: +357 80070017 | Sweden GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 |
Latvia SIA Berlin-Chemie/Menarini Baltic Tel: + 371 67103210 | United Kingdom (Northern Ireland) GlaxoSmithKline Trading Services Ltd. Tel: + 44 (0)800 221441 |
Last update of this leaflet:
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agency:https://www.ema.europa.eu
7. Step-by-step instructions for use of Nucala 40mg pre-filled syringe
Administer once every 4 weeks.
Follow these instructions on how to use the pre-filled syringe. Failure to follow these instructions may affect the proper functioning of the pre-filled syringe. You should also receive training on how to use the pre-filled syringe. Nucala pre-filled syringe is only for useunder the skin(subcutaneously).
How to store Nucala |
Before using Nucala |
The pre-filled syringe must be used only once and then discarded.
Preparation |
|
Find a comfortable, well-lit, and clean surface. Make sure you have:
|
2. Remove your pre-filled syringe |
Do notuse the syringe if the safety seal on the carton is broken. Do notremove the needle cap at this stage. |
3. Inspect and wait 30minutes before use |
Do notuse if the expiry date has passed. Do notheat the syringe in a microwave, with warm water or direct sunlight. Do notinject the solution if it is turbid or discoloured, or has particles. Do notuse the syringe if it is left out of the pack for more than 8 hours. Do notremove the needle cap at this stage. |
4. Choose the injection site |
Do notinject where the skin is bruised, sensitive, red, or hard. Do notinject within 5cm of the navel. |
5. Clean the injection site |
Do nottouch the injection site until you have finished. |
Inject |
6. Remove the needle cap |
Do notlet the needle touch any surface. Do nottouch the needle. Do nottouch the plunger at this stage, as you may accidentally expel the liquid and not receive the full dose. Do notexpel any air bubbles from the syringe. Do notput the needle cap back on the syringe. This may cause a needle injury. |
7. Start the injection |
|
8. Complete your injection |
|
Dispose |
9. Dispose of the used syringe |
|
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.